| Application no. and date | 15744702.0 (espacenet) (Federated) (European Patent Register), 20150722 | | Patent/reg. no. and date | DK/EP 3172209, 20201202 | | Publication date | 20170531 | | Priority no. and date | US 201462028865 P, 20140725 | | EP pub. no. and date |
EP 3172209 20170531 | | Effective date | | | Applicant/owner | Novartis AG, Lichtstrasse 35
4056 Basel, CH | | Applicant ref. no. | BT/GP/162663 | | Inventor | GONCALVES, Elisabete, c/o Novartis Pharma AG
Postfach
CH-4002 Basel, CH,
TAUCHMANN, Christin, c/o Novartis Pharma AG
Postfach
CH-4002 Basel, CH,
YEN, Shau-fong, c/o Novartis Pharma AG
Postfach
CH-4002 Basel, CH,
VIPPAGUNTA, Sudha, c/o Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, New Jersey 07936, US,
ZONG, Zhixin, c/o Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, New Jersey 07936, US | | Representative | Budde Schou A/S, Dronningens Tværgade 30, 1302 København K | | Opponent | | | IPC Class | A61J 3/06 (2006.01) , A61J 3/10 (2006.01) , A61K 31/4985 (2006.01) , A61P 35/00 (2006.01) , C07D 487/04 (2006.01) | | Title | TABLETFORMULERING MED 2-FLUOR-N-METHYL-4-[7-(QUINOLIN-6-YLMETHYL)IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMID | | Int. application no. | IB2015055561 | | Int. publication no. | WO2016012963 | | Related patent (certificate) | CA 2022 00056 | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
